Nipin (Nifedipine)

Nifedipine blocks L‑type calcium channels in vascular smooth muscle and heart muscle, preventing calcium entry. This leads to relaxation of arterial walls, vasodilation, decreased peripheral resistance, and reduced myocardial oxygen demand, which helps control blood pressure and chest pain.

The appropriate dose of Nipin is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and other factors. Patients should follow the dosage instructions provided by their healthcare professional.

The safety of nifedipine in pregnancy and lactation has not been definitively established. Healthcare providers should weigh potential benefits against possible risks before prescribing Nipin to pregnant or nursing women.

To request Nipin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nipin (nifedipine) belongs to the calcium channel blocker class, which primarily causes arterial vasodilation. Compared with beta‑blockers or ACE inhibitors, nifedipine may produce faster blood‑pressure reduction but can be associated with peripheral edema. Choice of therapy depends on patient profile and comorbidities.

Nipin should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, heat and direct sunlight to maintain its stability and potency.

Nipin is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious risks include severe hypotension, which can cause fainting or shock, and allergic reactions such as rash, swelling or anaphylaxis. Patients should seek immediate medical attention if they experience sudden dizziness, rapid heartbeat, or signs of an allergic response.

Nipin is contraindicated in patients with known hypersensitivity to nifedipine or other dihydropyridine calcium channel blockers, and in those with severe aortic stenosis or uncontrolled heart failure. Clinicians should evaluate each patient’s medical history before prescribing.